Question

In 2015 the biotech entrepreneur Martin Shkreli bought the marketing rights to Daraprim, which is a...

In 2015 the biotech entrepreneur Martin Shkreli bought the marketing rights to Daraprim, which is a drug that treats a parasitic infection. He then raised the price from $13.50 to $750 per pill. Is his conduct in violation of U.S. antitrust laws? In a country that prohibits “Excessive pricing,” would this price hike be illegal? Should the government intervene and pass legislation to put a price cap on the drug? What are the benefits and costs of such a policy?

Business   Economics   
0 0
Add a commentTranscribed image text
Next >

Homework Answers

Answer #1

0 0
Know the answer?
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Log In

Sign Up

Not the answer you're looking for?
Ask your own homework help question
Similar Questions
Martin Shkreli was CEO of Turing Pharmaceuticals when it purchased the 62-year-old drug called Daraprim and...
Martin Shkreli was CEO of Turing Pharmaceuticals when it purchased the 62-year-old drug called Daraprim and quickly raised the price of one pill from $13.50 to $750. As a result the average cost of treatment with the drug rose from about $1,130 to $63,000. Experts suggest it could rise to $634,000 for some patients.132 What is Daraprim? According to a Vanity Fair reporter, “Daraprim is on the World Health Organization’s List of Essential Medicines because it treats toxoplasmosis, a parasitic...
ADVERTISEMENT
Need Online Homework Help?

Get Answers For Free
Most questions answered within 1 hours.

Ask a Question
ADVERTISEMENT